Houke M. Klomp

Houke M. Klomp

Auto-generated profile, based on publicly available information

Houke M. Klomp

Department of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
JQJosine Quispel-Janssen
Josine Quispel-Janssen
VNVincent van der Noort
Vincent van der Noort
JVJeltje F. de Vries
Jeltje F. de Vries
MZMarion Zimmerman
Marion Zimmerman
FLFerry Lalezari
Ferry Lalezari
PBPaul Baas
Paul Baas
Malignant pleural mesothelioma (MPM) has limited treatment options and a poor outcome. Programmed death 1/programmed death ligand 1 (PD-L1) checkpoint inhibitors have proven efficacious in several cancer types. Nivolumab is a fully humanized monoclonal antibody against programmed death 1 with a favorable toxicity profile. In MPM, the immune system is considered to play an important role. We therefore tested nivolumab in recurrent MPM. In this single-center trial, patients with MPM received nivolumab 3 mg/kg intravenously every 2 weeks. Primary endpoint was the disease control rate at 12 weeks. Pre- and on-treatment biopsy specimens were obtained to analyze biomarkers for response. Of the 34 patients included, 8 patients (24%) had a partial response at 12 weeks and another 8 had stable disease resulting in a disease control rate at 12 weeks of 47%. One reached a partial response at 18 weeks. In 4 patients with stable disease, the tumor remained stable for more than 6 months. Treatment-related adverse events of any grade occurred in 26 patients (76%), most commonly fatigue (29%) and pruritus (15%). Grades 3 and 4 treatment-related adverse events were reported in 9 patients (26%), with pneumonitis, gastrointestinal disorders, and laboratory disorders mostly seen. One treatment-related death was due to pneumonitis and probably initiated by concurrent amiodarone therapy. PD-L1 was expressed on tumor cells in nine samples (27%), but did not correlate with outcome. Single-agent nivolumab has meaningful clinical efficacy and a manageable safety profile in pre-treated patients with mesothelioma. PD-L1 expression does not predict for response in this population.

4 June 2010 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
PSPaul Van Schil
Paul Van Schil
PBP. Baas
P. Baas
RGR. Gaafar
R. Gaafar
AMA.P. Maat
A.P. Maat
MPM. Van de Pol
M. Van de Pol
JMJan P. van Meerbeeck
Jan P. van Meerbeeck
The European Organisation for Research and Treatment of Cancer (EORTC; protocol 08031) phase II trial investigated the feasibility of trimodality therapy consisting of induction chemotherapy followed by extrapleural pneumonectomy and post-operative radiotherapy in patients with malignant pleural mesothelioma (with a severity of cT3N1M0 or less).Induction chemotherapy consisted of three courses of cisplatin 75 mg·m−2and pemetrexed 500 mg·m−2. Nonprogressing patients underwent extrapleural pneumonectomy followed by post-operative radiotherapy (54 Gy, 30 fractions). Our primary end-point was “success of treatment” and our secondary end-points were toxicity, and overall and progression-free survival.59 patients were registered, one of whom was ineligible. Subjects’ median age was 57 yrs. The subjects’ TNM scores were as follows: cT1, T2 and T3, 36, 16 and six patients, respectively; cN0 and N1, 57 and one patient, respectively. 55 (93%) patients received three cycles of chemotherapy with only mild toxicity. 46 (79%) patients received surgery and 42 (74%) had extrapleural pneumonectomy with a 90-day mortality of 6.5%. Post-operative radiotherapy was completed in 37 (65%) patients. Grade 3–4 toxicity persisted after 90 days in three (5.3%) patients. Median overall survival time was 18.4 months (95% CI 15.6–32.9) and median progression-free survival was 13.9 months (95% CI 10.9–17.2). Only 24 (42%) patients met the definition of success (one-sided 90% CI 0.36–1.00).Although feasible, trimodality therapy in patients with mesothelioma was not completed within the strictly defined timelines of this protocol and adjustments are necessary.

1 March 1999 in The Lancet
Verified
Journal Article
Closed access
HKHouke M Klomp
Houke M Klomp
GSGeert Hjj Spincemaille
Geert Hjj Spincemaille
ESEwout W Steyerberg
Ewout W Steyerberg
JHJ Dik F Habbema
J Dik F Habbema
HUHero van Urk
Hero van Urk

1 July 2012 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
EMErik M. von Meyenfeldt
Erik M. von Meyenfeldt
GGGea A. Gooiker
Gea A. Gooiker
WGWillem van Gijn
Willem van Gijn
PPPiet N. Post
Piet N. Post
CVCornelis J.H. van de Velde
Cornelis J.H. van de Velde
MWMichel Wouters
Michel Wouters

1 March 2016 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
WLWilson W.L. Li
Wilson W.L. Li
WBWim Jan P. van Boven
Wim Jan P. van Boven
JAJouke T. Annema
Jouke T. Annema
SESusanne Eberl
Susanne Eberl
HKHouke M. Klomp
Houke M. Klomp
BMBas A.J.M. de Mol
Bas A.J.M. de Mol
Large mediastinal masses are rare, and encompass a wide variety of diseases. Regardless of the diagnosis, all large mediastinal masses may cause compression or invasion of vital structures, resulting in respiratory insufficiency or hemodynamic decompensation. Detailed preoperative preparation is a prerequisite for favorable surgical outcomes and should include preoperative multimodality imaging, with emphasis on vascular anatomy and invasive characteristics of the tumor. A multidisciplinary team should decide whether neoadjuvant therapy can be beneficial. Furthermore, the anesthesiologist has to evaluate the risk of intraoperative mediastinal mass syndrome (MMS). With adequate preoperative team planning, a safe anesthesiological and surgical strategy can be accomplished.

15 September 2005 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
TGTom W. Geurts
Tom W. Geurts
PNPetra M. Nederlof
Petra M. Nederlof
MBMichiel W.M. van Den Brekel
Michiel W.M. van Den Brekel
LVLaura J. Van'T Veer
Laura J. Van'T Veer
DJDaphne de Jong
Daphne de Jong
MVMarie-Louise van Velthuysen
Marie-Louise van Velthuysen
Purpose: To distinguish a metastasis from a second primary tumor in patients with a history of head and neck squamous cell carcinoma and subsequent pulmonary squamous cell carcinoma.